Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma

BACKGROUND: The potential benefits and possible risks associated with combined nimotuzumab and concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma (NPC) have yet to be determined. METHODS: The databases PubMed, Web of Science, China National Knowledge Infrastructure, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhanzhan, Li, Yanyan, Yan, Shipeng, Fu, Jun, Zhou, Qin, Huang, Xinqiong, Shen, Liangfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694200/
https://www.ncbi.nlm.nih.gov/pubmed/29180878
http://dx.doi.org/10.2147/OTT.S141538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694200/
https://www.ncbi.nlm.nih.gov/pubmed/29180878
http://dx.doi.org/10.2147/OTT.S141538

Ejemplares similares